Stage IV Small Lymphocytic Lymphoma Terminated Phase 1 Trials for Alemtuzumab (DB00087)

IndicationStatusPhase
DBCOND0028635 (Stage IV Small Lymphocytic Lymphoma)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00947388Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)Treatment